These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 16216856)

  • 1. Impact on cardiovascular events of increasing high density lipoprotein cholesterol with and without lipid lowering drugs.
    Wei L; Murphy MJ; MacDonald TM
    Heart; 2006 Jun; 92(6):746-51. PubMed ID: 16216856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of established hypolipidemic drugs on HDL concentration, subclass distribution, and function.
    Gomaraschi M; Adorni MP; Banach M; Bernini F; Franceschini G; Calabresi L
    Handb Exp Pharmacol; 2015; 224():593-615. PubMed ID: 25523003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of cardiovascular events in patients at optimal values for combined lipid parameters.
    Stanek EJ; Sarawate C; Willey VJ; Charland SL; Cziraky MJ
    Curr Med Res Opin; 2007 Mar; 23(3):553-63. PubMed ID: 17357251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in HDL cholesterol and cardiovascular outcomes after lipid modification therapy.
    Ray K; Wainwright NW; Visser L; Witteman J; Breteler M; Ambegaonkar B; Hofman A; Stricker B; Wareham N; Khaw KT; Sandhu M
    Heart; 2012 May; 98(10):780-5. PubMed ID: 22447463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipid-lowering drug use and cardiovascular events after myocardial infarction.
    Klungel OH; Heckbert SR; de Boer A; Leufkens HG; Sullivan SD; Fishman PA; Veenstra DL; Psaty BM
    Ann Pharmacother; 2002 May; 36(5):751-7. PubMed ID: 11978147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipid concentrations and the use of lipid lowering drugs: evidence from a national cross sectional survey.
    Primatesta P; Poulter NR
    BMJ; 2000 Nov; 321(7272):1322-5. PubMed ID: 11090516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current lipid management and low cholesterol goal attainment in common daily practice in Spain. The REALITY Study.
    García Ruiz FJ; Marín Ibáñez A; Pérez-Jiménez F; Pintó X; Nocea G; Ahumada C; Alemao E; Yin D;
    Pharmacoeconomics; 2004; 22 Suppl 3():1-12. PubMed ID: 15669149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Lipid-Lowering Therapy on Mortality According to the Baseline Non-HDL Cholesterol Level: A Meta-Analysis.
    Masson W; Lobo M; Siniawski D; Molinero G; Huerín M; Nogueira JP
    High Blood Press Cardiovasc Prev; 2019 Aug; 26(4):263-272. PubMed ID: 31313082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Probucol Trial for Secondary Prevention of Atherosclerotic Events in Patients with Coronary Heart Disease (PROSPECTIVE).
    Yamashita S; Arai H; Bujo H; Masuda D; Ohama T; Ishibashi T; Yanagi K; Doi Y; Nakagawa S; Yamashiro K; Tanabe K; Kita T; Matsuzaki M; Saito Y; Fukushima M; Matsuzawa Y;
    J Atheroscler Thromb; 2021 Feb; 28(2):103-123. PubMed ID: 32336695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significance of high density lipoprotein-cholesterol in cardiovascular risk prevention: recommendations of the HDL Forum.
    Ascaso JF; Fernández-Cruz A; González Santos P; Hernández Mijares A; Mangas Rojas A; Millán J; Felipe Pallardo L; Pedro-Botet J; Pérez-Jiménez F; Pía G; Pintó X; Plaza I; Rubiés-Prat J;
    Am J Cardiovasc Drugs; 2004; 4(5):299-314. PubMed ID: 15449972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of selected lipid abnormalities: hypertriglyceridemia, isolated low HDL-cholesterol, lipoprotein(a), and lipid abnormalities in renal diseases and following solid organ transplantation.
    Rosas S; Szapary P; Rader DJ
    Cardiol Clin; 2003 Aug; 21(3):377-92. PubMed ID: 14621452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A case for lipid-lowering?
    Durrington P
    Diabet Med; 2000 Sep; 17 Suppl 2():4-5. PubMed ID: 11048824
    [No Abstract]   [Full Text] [Related]  

  • 14. [Update of lipid lowering therapy].
    Riesen WF; Mordasini RC
    Praxis (Bern 1994); 2008 Nov; 97(22):1179-84. PubMed ID: 18979436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid levels and the use of lipid-lowering agents in England and Scotland.
    Primatesta P; Poulter NR
    Eur J Cardiovasc Prev Rehabil; 2004 Dec; 11(6):484-8. PubMed ID: 15580059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of lipid-lowering therapy on the prevalence of dyslipidaemia in patients at high-risk of cardiovascular events in UK primary care - a retrospective database study.
    Jameson K; Amber V; D'Oca K; Mills D; Giles A; Ambegaonkar B
    Int J Clin Pract; 2013 Dec; 67(12):1228-37. PubMed ID: 23944233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of low high-density lipoprotein cholesterol and hypertriglyceridaemia in patients treated with hypolipidaemic drugs.
    Laforest L; Souchet T; Moulin P; Ritleng C; Desamericq G; Le Jeunne P; Schwalm MS; Van Ganse E
    Arch Cardiovasc Dis; 2009 Jan; 102(1):43-50. PubMed ID: 19233108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Update: clinical lipidology].
    Parhofer KG
    MMW Fortschr Med; 2013 Jul; 155(13):49-52; quiz 53-4. PubMed ID: 23964509
    [No Abstract]   [Full Text] [Related]  

  • 19. Influence of common genetic variation on blood lipid levels, cardiovascular risk, and coronary events in two British prospective cohort studies.
    Shah S; Casas JP; Gaunt TR; Cooper J; Drenos F; Zabaneh D; Swerdlow DI; Shah T; Sofat R; Palmen J; Kumari M; Kivimaki M; Ebrahim S; Smith GD; Lawlor DA; Talmud PJ; Whittaker J; Day IN; Hingorani AD; Humphries SE
    Eur Heart J; 2013 Apr; 34(13):972-81. PubMed ID: 22977227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What does the future hold for niacin as a treatment for hyperlipidaemia and cardiovascular disease?
    Ahmed MH
    J Cardiovasc Med (Hagerstown); 2010 Nov; 11(11):858-60. PubMed ID: 20686417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.